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Simian virus 40 (SV40) deletion mutants dlA2459 and dlA2475 express T antigens that lack the normal
carboxy terminus. These mutants are called host range/helper function (hrlhf) mutants because they form
plaques at 37C on BSC-1 and Vero monkey kidney cell lines but not on CV-lp monkey kidney cells. Wild-type
SV40 can provide a helper function to permit growth of human adenoviruses in monkey kidney cells; the hrlhf
mutants cannot. Progeny yields of hrlhf mutants are also cold sensitive in all cell lines tested. Patterns of viral
macromolecular synthesis in three cell lines (Vero, BSC-1, and CV-1) at three temperatures (40, 37, and 32°C)
were examined to determine the nature of the growth defect of hrlhf mutants. Mutant viral DNA replication
was similar to that of the wild type in all three cell lines, indicating that the mutations affect late events in the
viral lytic cycle. In mutant-infected Vero cells, in which viral yields were highest, late mRNA levels were similar
to those observed during wild-type infection. Levels of viral late mRNA from mutant-infected CV-1 and BSC-1
cells at 32 and 37°C were reduced relative to those of wild-type-infected cells. The steady-state level of the major
viral capsid protein, VP1, in mutant-infected CV-1 cells was reduced to the same extent as was late mRNA. The
synthesis of agnoprotein could not be detected in mutant-infected CV-1 cells but was readily detected in CV-1
cells infected by wild-type SV40. Primer extension analyses indicated that most late mRNAs from mutantinfected CV-1 cells utilize start sites downstream from the major wild-type cap site (nucleotide 325) and the
agnoprotein initiation codon (nucleotide 335). These results indicate that deletion of the carboxyl-terminal
domain of T antigen affects viral late mRNA production, both quantitatively and qualitatively. The agnoprotein
is detected late in the wild-type SV40 lytic cycle and is thought to play a role in the assembly or maturation of
virions. Reduced hrlhf progeny yields could result from decreased capsid protein synthesis and, in the absence
of detectable levels of agnoprotein, from inefficient use of available capsid proteins.

The simian virus 40 (SV40) large tumor (T) antigen is a
708-amino-acid polypeptide expressed throughout the infection cycle in permissive monkey kidney cells (for a review,
see reference 54). This protein is required for replication of
viral DNA (8, 34, 47, 49), autoregulation of SV40 early
transcription (1, 52), and transactivation of the SV40 late
promoter (6, 25, 26). T antigen is also essential for SV40 to
immortalize and to transform nonpermissive rodent cells to a
malignant phenotype (27, 50).
T antigen is modified posttranslationally by phosphorylation (51), glycosylation (22), acylation (32), ADP ribosylation
(19), and adenylylation (5). T antigen occurs in monomeric,
dimeric, and larger oligomeric forms and in complexes with
cellular proteins, including DNA polymerase a (45), p53
(33), and the retinoblastoma susceptibility gene product, Rb
(14). Different forms of T antigen may be involved in its
various biochemical activities. These activities include
ATPase (9, 18), helicase (46), and specific binding to the
SV40 origin of DNA replication (23, 39, 53). Each of these
activities has been mapped to specific regions of the Tantigen molecule (10, 13, 37). The viral DNA replication
function requires that these three activities be present in the
same T-antigen monomer (13, 55). Together, these domains
encompass sequences extending from approximately amino
acid 130 through 600 (13).
The extreme carboxyl terminus of large T antigen medi-

ates a distinct function, the host range/adenovirus helper
function (hrlhf). Most monkey cell lines infected by human
adenoviruses produce very low yields of viral progeny. The
block to productive adenovirus infection occurs at a late
stage of the adenovirus life cycle and can be overcome by
the carboxyl terminus of SV40 T antigen (17, 40). This can be
provided either by coinfection with SV40 or by infection
with adenovirus/SV40 hybrid viruses (for a review, see
reference 29). These hybrid viruses encode either large T
antigen, carboxyl-terminal fragments of T antigen, or adenovirus/SV40 fusion proteins containing the carboxyl terminus of large T. We have shown that the adenovirus helper
function activity of T antigen is contained within the carboxyl-terminal 34 amino acids of T antigen (11, 38).
Previously, we described deletion mutants of SV40
(dlA2459, dlA2465, and dlA2475) which do not express the
normal carboxyl terminus of large T (12, 13, 55). In addition
to being defective for adenovirus helper function, these
mutants are unable to form plaques on CV-lp monolayers at
37°C. This defect in plaque formation can be complemented
by SV40 mutants producing a T antigen with a normal
carboxyl terminus (55, 56) or by a mutant in which the
carboxyl-terminal 26 amino acids of large T are fused to the
amino-terminal 346 amino acids of VP1, the major capsid
protein (57). This demonstrates that the hrlhf function is
separable from the rest of T antigen.
The growth characteristics of the hrlhf mutants are cell
line and temperature dependent (12). The mutants form
plaques in CV-lp cells only at 40°C, in BSC-1 cells at 37 and
40°C, and in Vero cells at 32, 37, and 40°C. Interestingly,
human adenoviruses also grow productively in Vero cells
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(15) but not in CV-1 or other African green monkey kidney
(AGMK) cell lines tested. The growth properties of hrlhf
mutants indicate that the adenovirus helper function of T
antigen is also required by SV40 for productive infection in
CV-1 cells. Other hrlhf mutants have been described by
Manos and Gluzman (35) and by Pipas (36).
In our initial characterization of mutant dlA2459 (56), we
reported that the mutant genome replicates in CV-1 cells at
37°C and that a defect in late gene expression is responsible
for the reduced mutant progeny production. In this report,
we describe the patterns of viral late mRNA and VP1
synthesis during dlA2459 and dlA2475 infections of CV-1,
BSC-1, and Vero cells at various temperatures. In Vero
cells, hrlhf mutants produced approximately normal
amounts of late mRNA, VP1, and viral progeny. In contrast,
levels of late mRNA and VP1 were reduced in mutantinfected BSC-1 and CV-1 cells.
The agnoprotein, which is encoded in the leader region of
some SV40 late mRNAs, is detected late in the SV40 lytic
cycle (23) and is thought to be involved in the assembly and
maturation of virions (3, 7, 42). We could not detect the
agnoprotein after mutant infection of CV-1 cells. This agrees
with results obtained by Khalili et al. (27), who investigated
the properties of similar mutants. The major wild-type SV40
late mRNA start site is located upstream from the agnoprotein initiation codon (41, 54) and, therefore, most 16S late
mRNAs contain the sequences necessary to synthesize the
agnoprotein. In contrast, data presented here indicate that
the start sites of most late mRNAs produced in hrlhf
mutant-infected CV-1 cells mapped downstream of the agnoprotein initiation codon. There were no differences in the
16S late mRNA start sites used by wild-type SV40 and hrlhf
mutants in Vero cells. The very low yield of progeny virions
in mutant-infected CV-1 cells probably results from reduced
production of late mRNAS and capsid proteins and, because
of the absence of agnoprotein, from the inefficient use of
capsid proteins.

MATERIALS AND METHODS
Cells, viruses, and plasmids. The African green monkey
kidney cell lines CV-1, CV-lp, BSC-1, and Vero were
maintained in Dulbecco modified minimal essential medium
(DMEM) supplemented with 5 or 10% fetal calf serumpenicillin (10 U/ml)-streptomycin (10 ,ug/ml) in a humidified
atmosphere containing 7% CO2. CV-lp cells are a subline of
CV-1 cells used for plaque assays. CV-1 cells were used for
all other experiments.
The construction of mutant plasmids pdlA2459 and
pdlA2475 has been described previously (12, 55). To prepare
stocks of these mutants, Vero cells were transfected (57)
with mutant viral DNA which had been separated from
pBR322 sequences by digestion with EcoRI and recircularized by ligation at a low DNA concentration (5 ,ug/ml) with
T4 DNA ligase. Stocks of SV40 wild type (WT830), a
small-plaque strain (48), were prepared in Vero cells. Cells
were infected with SV40 at a multiplicity of infection of 0.05.
When most of the cells had rounded up but had not yet
detached, they were scraped from the plate, suspended in a
small volume of DMEM with 2% fetal calf serum, and
sonicated. The cell debris was removed by centrifugation,
and the viral stocks were stored at -80°C. Titers of wildtype and mutant stocks were determined by plaque assay on
monolayers of BSC-1 cells, as previously described (56).
Ribonuclease protection analysis of late viral mRNA. Confluent cell cultures were infected with mutant or wild-type
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virus at a multiplicity of infection of 5 and were incubated at
the temperatures indicated in the figure legends. Cytoplasmic RNA was prepared from cells harvested at 48 h (37 and
40°C cultures) or 96 h (32°C cultures) postinfection by the
method of White et al. (58). SP6 bacteriophage RNA polymerase was obtained from Promega Biotec (Madison, Wis.)
and used to prepare [32P]UMP-labeled RNA probes for use
in RNase protection mapping, following the directions provided by the enzyme supplier. RNA probes were synthesized from plasmid pSP64SVL (a generous gift from J.
Alwine), which contained the SV40 genome opened at its
BamHI site and inserted downstream from the SP6 promoter
in the orientation which permitted synthesis of RNA probes
complementary to SV40 late mRNAs. The plasmid was
linearized at the ApaI site (SV40 nucleotide 2258). After
denaturation, cytoplasmic RNA was annealed to an excess
of probe RNA overnight at 60°C, and hybrids were digested
at 37°C with RNase A (40 ,ug/ml; Sigma Chemical Co., St.
Louis, Mo.) and T1 (2 ,ug/ml; Sigma). Protected fragments
were analyzed by electrophoresis on 6% polyacrylamide-7
M urea gels, followed by autoradiography.
Analysis of viral capsid protein. At various times after
infection, cells were harvested in lysing buffer (0.15 M NaCl,
0.02 M Tris hydrochloride [pH 8.0], 1% Nonidet P-40) from
cultures infected with dlA2475, dlA2459, or wild-type SV40.
Lysates from equal numbers of infected cells were electrophoresed on sodium dodecyl sulfate (SDS)-polyacrylamide
gels and transferred to nitrocellulose by electroblotting.
Blots were incubated first with rabbit antiserum to SDSdisrupted SV40 virions, and then with goat anti-rabbit immunoglobulin G conjugated to alkaline phosphatase (Sigma).
Immunodetection was with 5-bromo-4-chloro-3-indolyl
phosphate and Nitro Blue Tetrazolium, as described by
Blake et al. (4). The SV40 antiserum recognizes only VP1.
Analysis of agnoprotein. dlA2459-, dlA2475-, or wild-typeinfected CV-1 cells were pulsed-labeled with [14C]arginine
(323.5 mCi/mmol; New England Nuclear-DuPont) in arginine-free DMEM for 1 h. Cells were lysed in SDS sample
buffer (7 M urea, 7 mM sodium phosphate, monobasic, 1%
SDS, 0.1% 2-mercaptoethanol, 0.01% bromophenol blue)
and analyzed on a polyacrylamide gel containing 0.1 M
sodium phosphate (pH 7.2)-0.1% SDS-6 M urea-15% polyacrylamide-bisacrylamide (30:0.8) (44).
Primer extension analysis. A 30-base-pair (bp) oligonucleotide primer complementary to late mRNA and extending
from SV40 nucleotides 1498 to 1468 was synthesized and
labeled by using [a-32P]ATP and T4 polynucleotide kinase.
Samples (10 ,ug) of cytoplasmic RNA extracted from mutantand wild-type-infected cells were denatured with primer in 5
pl of hybridization buffer (80% formamide, 40 mM piperazine-N,N'-bis[2-ethanesulfonic acid] [PIPES] [pH 6.7], 0.4
M NaCl, 1 mM EDTA) at 85°C for 10 min and annealed at
60°C for 4 h. Reaction volumes were brought to 50 ,ul in 50
mM Tris (pH 8.5)-10 mM MgCl2-40 mM KCl-1 mM dithiothreitol-250 ,uM of each deoxynucleotide triphosphate; 5 U
of avian myelobastosis virus reverse transcriptase was
added, and samples were incubated at 42°C for 1 h. RNA
was hydrolyzed in 0.5 N NaOH; reaction mixtures were
neutralized with 0.5 N HCl and ethanol precipitated, and
cDNAs were analyzed by electrophoresis on 6% polyacrylamide-7 M urea gels.
RESULTS

The carboxyl terminus of SV40 large T antigen is a
separate and separable functional domain which is required
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FIG. 1. (A) Nucleotide sequence of the 3' end of the early region
of the SV40 genome. Shown are the locations of the deletions in the
dlA2459 and dlA2475 genomes, the termination codon for large T
antigen, and the early mRNA polyadenylation signal. (B) Sequence
of the carboxyl-terminal portion of the T antigens encoded by
wild-type SV40, dlA2459, and dlA2475. The single line refers to
residues in mutant proteins that are identical to the wild type. The
boxed area represents residues that are absent from the dIA2475 T
antigen.

for productive infection of most monkey kidney cell lines by
SV40 (35, 36, 57) or human adenoviruses (16, 20). We
constructed SV40 mutants dlA2459 (55) and dlA2475 (12)
whose T antigens lack this domain and have shown that
these mutants have a host range and cold-sensitive phenotype (12, 57). Figure 1 shows the structure of the 3' end of
the early region of the SV40 genome, the sequences deleted
in the genomes of mutants dlA2459 and dlA2475, and the
corresponding T-antigen amino acid sequences. dlA2459 has
a 14-bp deletion of nucleotides 2798 to 2785 that causes a
reading frame shift and the production of a 673-amino-acid T
antigen lacking the carboxyl-terminal 35 amino acids of
wild-type T antigen. dlA2475 is deleted from nucleotides
2770 through 2669 and produces a 682-amino-acid T antigen
that lacks the 26 carboxyl-terminal amino acids. Both contain non-wild-type amino acids at their carboxyl termini. The
growth characteristics of these two mutants are very similar,
but the growth defect is slightly more severe for dlA2475
than for dlA2459. This could result from dlA2475 having 12
non-wild-type amino acids at the carboxyl terminus, while
dIA2459 has only 3 non-wild-type amino acids (Fig. 1).
In our previous study (12), we reported that mutant
progeny yields were decreased 75- to 80-fold in CV-1 cells at
37 and 40°C, 25- to 60-fold in BSC-1 cells, and about 10-fold
in Vero cells, relative to those of the wild type. In all cell
lines examined, mutant yields were reduced most severely at
32°C. We showed previously that dlA2459 DNA replicated
normally in CV-lp cells at 37°C (57), and we concluded that
the host range/helper function of large T antigen is required
after the onset of viral DNA replication. We have since
analyzed dlA2459 and dlA2475 DNA replication in Vero and
BSC-1 cells, as well as CV-1 cells, at 37 and 32°C (data not

shown). In all cases, we found that mutant viral DNA
replicated nearly as efficiently as wild-type DNA. Other
laboratories have analyzed similar carboxyl-terminal T-antigen mutants and reported them to be competent for viral
DNA replication (35, 36). In an effort to understand the
molecular basis of the host range and cold-sensitive defects
of the hrlhf mutants, we compared the patterns of late viral
macromolecular synthesis in various monkey kidney cell
lines infected at different temperatures by wild-type SV40,
dlA2475, or dlA2459.
Levels of late viral mRNA. We examined late viral mRNA
levels in CV-1, BSC-1, and Vero cells infected with dlA2459,
dlA2475, or wild-type SV40. Total cytoplasmic RNA was
isolated from infected cells and hybridized to an RNA probe
that protects the 3' ends of all SV40 late mRNAs. After
RNase digestion, the protected fragments were analyzed on
denaturing polyacrylamide gels (Fig. 2). Figure 2A shows the
results of an analysis performed on RNA from mutant and
wild-type infections of the three cell lines incubated at 37°C.
Equal quantities of viral late mRNA were detected in mutant- and wild-type-infected Vero (Fig. 2A, lanes 8, 9, and
10) and BSC-1 (Fig. 2A, lanes 5, 6, and 7) cells. However,
decreased levels of mutant viral late mRNA were observed
in mutant-infected CV-1 cells at 37°C (compare Fig. 2A,
lanes 3 and 4, with Fig. 2A, lane 2). This indicates that the
absence of the normal carboxyl terminus of T antigen
correlated with decreased levels of SV40 late mRNA in CV-1
cells but not in Vero or BSC-1 cells.
Mutant viral yields are most cold sensitive in CV-1 cells.
We compared viral late mRNA levels in mutant- and wildtype-infected CV-1 cells incubated at 32, 37, and 40°C (Fig.
2B). The levels of mutant viral late mRNAs were clearly
affected by incubation temperature. Very little viral late
mRNA from mutant-infected cells was detected at 32°C (Fig.
2B, lanes 2 and 3); slightly higher levels of late mRNAs were
detected in mutant-infected cultures maintained at 40°C (Fig.
2B, lanes 9 and 10) than at 37°C (Fig. 2B, lanes 6 and 7).
Interestingly, wild-type late mRNA production was slightly
cold sensitive (compare Fig. 2B, lanes 1 and 4), which
correlates with the observation that even wild-type SV40 is
slightly cold sensitive in CV-1 cells (12).
Viral capsid protein synthesis. We compared the accumulation of VP1, the SV40 major capsid protein, in mutant- and
wild-type-infected Vero and CV-1 cells (Fig. 3). These two
cell lines are the most and least permissive, respectively, for
growth of the hrlhf mutants. Lysates for Western blotting
were harvested on three consecutive days after infection at
37°C (Fig. 3B and E) and 40°C (Fig. 3C and F) and on four
consecutive days after infection at 32°C (Fig. 3A and D) to
accommodate the slower time course of infection at 32°C. In
Vero cells (Fig. 3D to F), VP1 accumulated to similar levels
in wild-type- and mutant-infected cultures. The slightly
lower levels of VP1 in dlA2475 infection versus dlA2459
(Fig. 3E) were observed reproducibly. In contrast, in CV-1
cells (Fig. 3A to C), VP1 accumulation during mutant
infection was reduced significantly relative to that during
wild-type infection. These reduced levels of capsid protein
correspond to the observed levels of late mRNA. At 37°C in
CV-1 cells, in which levels of mutant late mRNAs were
reduced 5- to 10-fold (Fig. 2B), VP1 levels were reduced to
a similar degree. The stability of VP1 was also examined by
pulse-chase labeling of mutant- and wild-type-infected Vero
and CV-1 cells incubated at different temperatures. VP1 had
the same stability in mutant- and wild-type-infected cells
(data not shown).
Synthesis of agnoprotein. A 61-amino-acid protein, the
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FIG. 2. RNase protection analysis of SV40 late mRNAs. Total cytoplasmic RNA was prepared from infected or mock-infected cultures
and annealed with [32P]-labeled antisense RNA probe. After hybridization, RNA was digested with RNase A and T1 and the protected RNA
hybrids were analyzed on denaturing 6% polyacrylamide-urea gels, as described in Materials and Methods. In hybrids between probe and
SV40 late mRNAs, a 275-nucleotide band is protected (arrows). (A) Total cytoplasmic RNA was prepared for protection analysis from CV-1
(lanes 1 to 4), BSC-1 (lanes 5 to 7), or Vero (lanes 8 to 10) cells infected with wild-type SV40 (lanes 2, 5, and 8), dIA2459 (lanes 3, 6, and 9),
or dlA2475 (lanes 4, 7, and 10), or the cells were mock infected (lane 1). (B) Total cytoplasmic RNA was prepared for protection analysis from
CV-1 cells infected with wild-type SV40 (lanes 1, 4, and 8), dlA2459 (lanes 2, 6, and 9), dIA2475 (lanes 3, 7, and 10), or from mock-infected
cells (lane 5). Incubation temperatures were 32°C (lanes 1 to 3), 37°C (lanes 4 to 7) or 40°C (lanes 8 to 10).

agnoprotein, is encoded in the leader region of the major
class of SV40 16S late mRNAs (23). Carswell and Alwine (7)
suggested a role for this protein in the efficient nuclear
localization of VP1. A direct interaction between the agnoprotein and VP1 in the assembly of virions was suggested
from studies of pseudorevertants of mutants that do not
produce the agnoprotein (3). A role for the agnoprotein in the
efficient release of virions from SV40-infected cells was
proposed by Resnick and Shenk (42). Since progeny fields in
CV-1 cells infected by hrlhf mutants were reduced to a
greater extent (50- to 100-fold) than were the levels of VP1
(5- to 10-fold), we examined the production of agnoprotein in
mutant-infected CV-1 cells.
The agnoprotein is rich in arginine and can be distinguished from other cellular and viral proteins by in vivo
labeling with [14C]arginine and fractionation of the smallmolecular-weight proteins on polyacrylamide-urea gels (23,
44). Figure 4 shows the results of such an analysis. Although
a [14C]arginine-labeled protein of the appropriate size was
readily detected 40 h after infection by wild-type SV40 (Fig.
4, lane 1), this protein could not be detected in mutant- or
mock-infected CV-1 cells (Fig. 4, lanes 2 to 4), even after
prolonged exposure of the autoradiogram (data not shown).
This result confirms the finding that agnoprotein is not
produced in CV-1 cells infected by similar SV40 hrlhf
mutants (27) and suggests that the failure to produce agnoprotein in CV-1 cells is a general property of mutants of this
class.
Analysis of viral late mRNA start sites. SV40 16S late
mRNAs have multiple cap sites and therefore contain various amounts of leader sequence upstream from the VP1
coding region (41, 54). Those that start at or 5' to the major
cap site (nucleotide 325) and have the most common splicing
pattern encode the agnoprotein (Fig. SB). This is approximately 80% of 16S late mRNAs in wild-type-infected cells
(41). 16S messages with other splicing patterns or those
using cap sites downstream of the agnoprotein AUG (nucle-

otide 335) do not encode the agnoprotein. A failure to
produce agnoprotein could reflect either defects in translation of 16S mRNAs encoding the agnoprotein or alterations
in 16S late mRNA structures. To distinguish among these
possibilities, we mapped the cap sites of 16S late mRNAs
present in mutant- and wild-type-infected CV-1 and Vero
cells by primer extension analysis. Autoradiograms of the
reverse-transcribed products are shown in Fig. SA. In Vero
cells (Fig. 5A, lanes 5 to 7), identical patterns of primer
extension were seen after mutant and wild-type infections. A
major band corresponding to transcription initiation at nucleotide 325 is indicated.
In CV-1 cells, the band corresponding to transcription
initiation at the major cap site (nucleotide 325) was the major
band seen in wild-type-infected cells (Fig. 5A, lane 1) but
was barely detectable in cells infected by dlA2459 (Fig. 5A,
lane 2) or dlA2475 (Fig. 5A, lane 3). For both mutants, the
major primer extension products detected corresponded to
species of SV40 16S late mRNA that are present but relatively rare in wild-type-infected cells and that initiate downstream (nucleotides 465 and 482) of the agnoprotein AUG at
nucleotide 335. Although start sites at nucleotides 465 and
482 were reported by Reddy et al. (41), they note that the site
at nucleotide 465 is next to an AU sequence known to be
adjacent to capped structures on SV40 late mRNAs (21),
whereas the start site at nucleotide 482 is not. Our present
data do not exclude the possibility that either or both of
these extension products arose from premature termination
of the cDNA. However, it is clear from our data that 16S late
mRNAs able to encode the agnoprotein were very rare in
mutant-infected CV-1 cells. We have repeated this experiment several times under different conditions; we have never
observed a prominent band corresponding to the major start
site at nucleotide 325 in analyses using multiple different
samples of mutant late mRNA.
We conclude from this analysis that synthesis of the
agnoprotein does not occur at detectable levels after hrlhf
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FIG. 3. Western immunoblotting analysis of SV40 capsid protein accumulation. Lysates from mutant-, wild-type-, or mock-infected CV-1
(panels A to C, respectively) and Vero cells (panels D to F, respectively) that had been cultured at 32°C (panels A and D), 37°C (panels B
and E), or 40°C (panels C and F) were electrophoresed on 8% SDS-polyacrylamide gels. After transfer to nitrocellulose, capsid protein was
detected by treatment first with rabbit antiserum to SDS-disrupted SV40 virions, which recognizes only VP1, and then with goat anti-rabbit
immunoglobulin G conjugated to alkaline phosphatase. Immunodetection was as described in Materials and Methods. Numbers above the
lanes indicate the days postinfection (dpi) that lysates were prepared.

mutant infection of CV-1 cells because the 16S late mRNAs
produced lack the coding information for this protein. Both
the steady-state levels and the structures of the SV40 late
mRNAs were altered in hrlhf mutant-infected CV-1 cells.

DISCUSSION
SV40 deletion mutants which produce large T antigens
that lack the normal carboxyl terminus show host range and
cold-sensitive behavior for plaque formation and progeny
yield and are also absolutely defective for adenovirus helper
function (12). They are referred to as hrlhf mutants.
In this study, we analyzed the levels of viral late mRNA
and viral late proteins after mutant and wild-type SV40
infection of three AGMK cell lines. Of the lines tested, CV-1
cells are the most restrictive and Vero cells are the most
permissive for hrlhf mutant growth. BSC-1 cells are intermediate for mutant growth. Since the mutants show cold
sensitivity, some experiments were conducted at 32, 37, and
40°C. Our results can be summarized as follows.
(i) Viral late mRNA accumulated to similar levels in Vero
and BSC-1 cells infected by hrlhf mutants and wild-type

SV40 but not in CV-1 cells (Fig. 2A). In CV-1 cells at 37°C,
the mutants accumulated only 10 to 20% as much late viral
mRNA as wild type. Even less late message was present at
32°C in mutant-infected CV-1 cells. The levels of mutant late
message were somewhat greater in CV-1 cells incubated at
400C.
(ii) The major capsid protein VP1 accumulated to nearly
equal levels in Vero cells infected with wild-type SV40 or
hrlhf mutants (Fig. 3). However, mutant-infected CV-1 cells
failed to accumulate VP1 to wild-type levels. The extent of
the decrease in the amount of VP1 in mutant-infected CV-1
cells reflected the decreased level of late mRNA. Therefore,
the hrlhf mutation appears to affect late mRNA accumulation but not its translation. Whether there is a defect in
transactivation, in transcription elongation, or at some posttranscriptional step in mRNA metabolism will require additional studies.
(iii) Synthesis of the agnoprotein was detected in wildtype-infected CV-1 cells but not in hr/hf-infected CV-1 cells
(Fig. 4). Primer extension analysis showed that the agnoprotein could not be produced at detectable levels during mutant
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FIG. 4. Analysis of the synthesis of the agnoprotein. Plates (35
mm diameter) of confluent CV-1 cells were infected with wild-type
SV40 (lane 1), dlA2459 (lane 2), or dIA2475 (lane 3), or they were
mock infected (lane 4). At 40 h postinfection, cells were labeled with
5 ,uCi of [14C]arginine per plate for 1 h in DMEM lacking arginine
plus 2% dialyzed fetal calf serum. Lysates were harvested and
analyzed on an SDS-15% polyacrylamide gel containing 6 M urea,
as described in Materials and Methods. Positions of 14C-labeled
molecular size markers and the agnoprotein (Agno) are indicated.
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infection of CV-1 cells because of altered patterns of mutant
late mRNA start sites. Although the mutants and wild type
showed identical patterns of mRNA cap sites in Vero cells,
almost all of the 5' ends of mutant viral 16S mRNAs in CV-1
cells mapped downstream of the agnoprotein initiation
codon (Fig. 5). The major sites used in mutant-infected CV-1
cells are sites which are used to form minor species of 16S
late mRNA during wild-type infection (41, 54).
The results of our primer extension analyses do not agree
with conclusions reached by Khalili et al. (27), who reported
no differences in late mRNA leader structures in CV-lp cells
infected with wild-type SV40 and hrlhf mutants similar to
our mutants. The primer used in their studies (nucleotides
460 to 520) would not have detected late mRNAs initiated at
nucleotides 465 and 482, which we found to be the major
species of 16S late mRNA in mutant-infected CV-1 cells. We
also examined the cap sites of 19S late mRNAs in mutantand wild-type-infected CV-1 and Vero cells. In Vero cells,
mutant and wild-type late 19S mRNAs use the same cap sites
with the same frequencies; in CV-1 cells, most mutant 19S
late mRNA start sites map downstream from the major
wild-type site (T. Stacy and C. N. Cole, unpublished data).
Although the conclusions reached by Khalili et al. (27) do
not agree with ours, the data in their report clearly show
decreased use of the major cap site at nucleotide 325 in 19S
late mRNA isolated from mutant-infected CV-lp cells.
Vero cells are most permissive for hrlhf mutant infection;
wild-type amounts of viral DNA, late mRNA, and VP1 were
produced. Previous studies suggested that mutant viral progeny yields were reduced up to 10-fold in Vero cells relative
to those of the wild type. We now believe that the actual
virion yields in mutant-infected Vero cells are higher than
yields calculated from standard plaque assays. These plaque
assays are performed with BSC-1 cells because monolayers
of Vero cells do not survive long enough for use in these
assays. Approximately 15% of mutant-infected BSC-1 cells
produce sufficient virions to form plaques, whereas plaques
are formed from nearly 100% of wild-type-infected cells (T.
Stacy and C. N. Cole, manuscript in preparation).
Although the two deletion mutants, dlA2459 and dlA2475,
behaved similarly with respect to host range and helper
function properties, they are not identical. dlA2459, with a
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FIG. 5. Primer extension analysis of SV40 late 16S mRNA 5'
ends. (A) CV-1 and Vero cells were infected with wild-type SV40
(lanes 1 and 5), dIA2459 (lanes 2 and 6), or dIA2475 (lanes 3 and 7),
or they were mock infected (lane 4). Cytoplasmic RNA was harvested at 48 h postinfection, and primer extension reactions were
performed as described in Materials and Methods. 32P-labeled
cDNA products were analyzed on 6% polyacrylamide-7 M urea
gels. The SV40 nucleotide positions of 16S mRNA start sites (41, 55)
are indicated by arrows; the positions of nucleic acid size markers
are also shown. (B) The SV40 late leader region and splice junctions
for 16S mRNAs are shown. The translation initiation and termination codons for the agnoprotein and the initiation codon for VP1 are
shown above the line. The major 16S mRNA cap site at nucleotide
position 325, as well as minor cap sites at positions 465 and 482 are
indicated below the line. The splice donor and acceptor sites are in
italics. The 32P-labeled 30-base oligonucleotide primer extends from
SV40 nucleotides 1498 to 1468.

14-bp frame-shift deletion upstream of the region encoding
the carboxyl terminus of T antigen, can revert to a wild-type
phenotype with the deletion of only 1 more bp in the vicinity
of the original deletion, thus restoring the wild-type Tantigen reading frame. We have determined the proportion
of revertants in the progeny of a single growth cycle of
dlA2459 to be approximately 1% (Stacy and Cole, unpublished results). The proportion depends on the timing of the
initial reversion mutation(s) and may also involve cellular
factors. In contrast, the wild-type T-antigen carboxyl terminus cannot be restored to dlA2475 T antigen by a single
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mutational event, since the DNA for this region is not
present in dlA2475 (12). We find that this mutant reverts to
the wild-type phenotype at an extremely low rate, if at all
(Stacy and Cole, unpublished data). We consistently obtained dlA2475 viral yields that were somewhat less than
dlA2459 yields, and we often observed less viral gene
product (compare dlA2475 and dlA2459 VP1 accumulation in
Vero cells in Fig. 3E). This may reflect the participation of
second-site revertants during dlA2459 infection.
The late mRNAs of dlA2475 and dlA2459 also differ. The
deletion of dlA2475 removes sequences normally located in
the 3' untranslated region of late mRNA, between the
AAUAAA and the poly(A) tail; the deletion in dlA2459 is
located outside of sequences found in late mRNA. It is
possible that dIA2475 and dlA2459 late mRNAs are translated with somewhat different efficiencies because of these
structural differences.
Human adenoviruses grow productively in Vero cells (15)
but not in other AGMK cell lines. This finding suggests that
the function provided by the carboxyl terminus of T antigen
is not required by human adenoviruses or by SV40 for
productive infection of Vero cells. CV-1 cells, on the other
hand, have more stringent requirements for productive infection by both SV40 and human adenoviruses. The block to
productive infection of CV-1 cells by adenovirus results in a
reduction in the quantity and translatability of adenovirus
late mRNAs (2, 30) which results in reduced amounts of
adenovirus capsid proteins, leading to reduced progeny
virion formation. Adenovirus host range mutants that grow
productively in CV-1 cells have been isolated and have
mutations that map to the adenovirus 72,000-Mr singlestranded DNA-binding protein (31, 43). It is not known
whether the carboxyl terminus of T antigen and the altered
DNA-binding protein act through the same mechanism to
promote the growth of adenovirus in monkey kidney cells.
The fact that both human adenoviruses and SV40 require the
same region of T antigen for productive infection of CV-1
cells strongly suggests that the same biochemical activity of
T antigen is important for human adenovirus and hrlhf
mutant growth.
The hrlhf mutant phenotype is complex. Mutants produce
viral DNA in CV-1 cells but fail to accumulate wild-type
levels of late mRNAs or the capsid protein VP1. These
mutants also fail to produce the agnoprotein in CV-1 cells.
The mutants will form plaques on CV-1 cells that express the
agnoprotein constitutively; however, agnoprotein supplied
in trans does not restore the mutant progeny yields to
wild-type levels (Stacy and Cole, in preparation). This
finding suggests that providing the agnoprotein permits efficient use of available capsid proteins but cannot restore late
mRNA to wild-type levels. The primary defect caused by
hrlhf mutations is still not known. The data presented here
indicate that these mutations result in decreased levels of
late mRNA and that the late mRNAs have an altered
distribution of cap sites. This could reflect a direct effect of
T antigen on late transcription or an indirect effect due to
alterations in the nature of the progeny DNA molecules
which serve as templates for late transcription.
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